Understand the source comparison
Mechanism of Action: Membrane Stabilisation vs Nuclear Receptor Activation
SS-31's active sequence (D-Arg-Dmt-Lys-Phe-NH₂) carries alternating positive charges that electrostatically bind cardiolipin, a phospholipid enriched 1000-fold in the inner mitochondrial membrane compared to other cellular membranes. Cardiolipin maintains cris
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SS-31's active sequence (D-Arg-Dmt-Lys-Phe-NH₂) carries alternating positive charges that electrostatically bind cardiolipin, a phospholipid enriched 1000-fold in the inner mitochondrial membrane compared to other cellular membranes. Cardiolipin maintains cristae architecture. The folded membrane structures that house ATP synthase complexes. And when cardiolipin oxidises under stress, cristae unfold, electron transport chain efficiency drops, and cytochrome c leaks into the cytosol triggering apoptosis. SS-31 prevents this cascade by sterically shielding cardiolipin from reactive oxygen species (ROS) and stabilising its interaction with respiratory chain complexes. The peptide doesn't activate signalling pathways; it physically occupies a vulnerable molecular site.
- SS-LUP-332 operates through estrogen-related receptor gamma (ERRγ), an orphan nuclear receptor that regulates mitochondrial biogenesis, oxidative metabolism, and thermogenesis by binding DNA response elements in the promoter regions of genes like PGC-1α, TFAM, CPT1A, and UCP3. When SS-LUP-332 binds ERRγ, it induces a conformational change that recruits coactivator proteins (PGC-1α, SRC-1) and increases transcription of these target genes. The result is more mitochondria per cell, enhanced fatty acid oxidation capacity, and increased oxygen consumption. This is transcriptional reprogramming, not membrane repair. In skeletal muscle models, SS-LUP-332 increased mitochondrial DNA copy number by 68% after 21 days, while SS-31 showed no effect on mitochondrial density in non-stressed tissue.
- The functional implication: SS-31 works immediately (detectable cardiolipin binding within minutes of administration) but requires ongoing presence to maintain protection. Discontinuation returns mitochondria to baseline vulnerability. SS-LUP-332 requires days to weeks for gene expression changes to manifest as protein-level alterations, but effects persist for 7–14 days after cessation due to the half-life of newly synthesised mitochondrial proteins. One is an acute intervention; the other is metabolic conditioning.